Microchemical Journal, Journal Year: 2024, Volume and Issue: unknown, P. 112043 - 112043
Published: Oct. 1, 2024
Language: Английский
Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 97, P. 105770 - 105770
Published: May 11, 2024
Language: Английский
Citations
16
Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)
Published: Oct. 31, 2024
Chitosan nanoparticles (NPs) are well-recognized as promising vehicles for delivering anticancer drugs due to their distinctive characteristics. They have the potential enclose hydrophobic molecules, thereby enhancing solubilities, permeabilities, and bioavailabilities; without use of surfactant, i.e., through surfactant-free solubilization. This allows higher drug concentrations at tumor sites, prevents excessive toxicity imparted by surfactants, could circumvent resistance. Moreover, biomedical engineers formulation scientists can also fabricate chitosan NPs slowly release agents. keeps site longer, makes therapy more effective, lowers frequency dosing. Notably, some types cancer cells (fallopian tube, epithelial tumors ovary, primary peritoneum; lung, kidney, ependymal brain, uterus, breast, colon, malignant pleural mesothelioma) overexpression folate receptors (FRs) on outer surface, which lets folate-drug conjugate–incorporated target kill them effectively. Strikingly, there is evidence suggesting that excessively produced FR&αgr (isoforms FR) stays consistent throughout treatment in ovarian endometrial cancer, indicating resistance conventional treatment; this regard, folate-anchored overcome it improve therapeutic outcomes. Interestingly, overly expressed FRs present only certain types, a biomarker predicting effectiveness FR-targeted therapy. On other hand, folate-modified enhance oral absorption medicines, especially drugs, pave way effective long-term low-dose metronomic scheduling poorly soluble permeable drugs. In review, we talked briefly about techniques used create, characterize, tailor chitosan-based NPs; delved deeper into applications folate-engineered treating various types. Schematic illustration ligand-drug incorporated its advantage cancer. Figure created with BioRender.Com.
Language: Английский
Citations
8
International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125273 - 125273
Published: Jan. 1, 2025
Language: Английский
Citations
1
Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)
Published: July 27, 2024
This study focused on developing an optimal formulation of liposomes loaded with bee venom (BV) and coated PEG (BV-Lipo-PEG). The were characterized using dynamic light scattering, transmission electron microscopy, Fourier transform infrared spectroscopy. Among the liposomal formulations, F3 exhibited narrowest size distribution a low PDI value 193.72 ± 7.35, indicating minimal agglomeration-related issues more uniform distribution. BV-Lipo-PEG demonstrated remarkable stability over 3 months when stored at 4 °C. Furthermore, release drug from formulations was found to be pH-dependent. Moreover, favorable entrapment efficiencies, values reaching 96.74 1.49. anticancer potential nanocarriers evaluated through MTT assay, flow cytometry, cell cycle analysis, real-time experiments. functionalization system enhanced endocytosis. IC50 showed notable decrease compared both free BV-Lipo alone, signifying that is effective in inducing death A549 lines. higher apoptotic rate lines other samples. In treated BV-Lipo-PEG, expression levels MMP-2, MMP-9, Cyclin E genes decreased, whereas Caspase3 Caspase9 increased. These findings suggest delivering BV via PEGylated holds significant promise for treatment lung cancer.
Language: Английский
Citations
7
European Polymer Journal, Journal Year: 2024, Volume and Issue: 218, P. 113338 - 113338
Published: July 26, 2024
Language: Английский
Citations
6
International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: unknown, P. 124994 - 124994
Published: Nov. 1, 2024
Language: Английский
Citations
4
Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 36
Published: Feb. 18, 2025
Breast cancer remains one of the significant health issues across globe, being diagnosed in millions women worldwide annually. Conventional therapeutic options have substantial adverse effects due to their non-specificity and limited drug bioavailability. Niosomes, novel delivery systems formed from non-ionic surfactants, with or without cholesterol charge-inducing agents, are used as treating BC. Their formulation by various methods enhances efficacy bioavailability minimizes side effects. Niosomal tamoxifen exhibits target enhanced stability, whereas docetaxel methotrexate show sustained controlled release, respectively.5-Fluorouracil, doxorubicin, paclitaxel, cyclophosphamide, epirubicin improved cytotoxic against BC when combined other agents. Furthermore, repurposed niosomal formulations anti-cancer drugs penetration, reduced tumor volume, significantly anti-tumor effect. This review article focuses on composition niosomes application treatment then examines how could contribute research.
Language: Английский
Citations
0
Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 101, P. 106286 - 106286
Published: Oct. 11, 2024
Language: Английский
Citations
0
Microchemical Journal, Journal Year: 2024, Volume and Issue: unknown, P. 112043 - 112043
Published: Oct. 1, 2024
Language: Английский
Citations
0